Description du livre
Every rare disease begins with a patient and a question: why isn’t there a treatment? Too often, the answer isn’t scientific, it is financial. The science exists. The will does exist. But the funding pathways don’t. For decades, rare disease research has been caught between two worlds: public grants that are too short-term to sustain discovery, and private investment that sees too little market potential to engage. Thousands of promising ideas never leave the lab, not because they failed, but because the funding system did. This book is written to change that. Across the world, funders, patient organizations, and scientists are experimenting with bold, hybrid approaches that blend the discipline of finance with the purpose of medicine. Venture philanthropy, public–private partnerships, social impact bonds, and collaborative consortia are not financial curiosities, they are survival strategies for rare disease innovation. The aim of "Alternate Funding Mechanisms in Rare Diseases" is simple: to make these approaches understandable, usable, and actionable. Whether you lead a foundation, manage a research program, or simply care deeply about someone living with a rare condition, this book shows how to turn financial creativity into measurable impact.
ABOUT THE AUTHOR
Dr. Levine, President Fondation Ipsen, has three decades of experience in the healthcare sector principally at Mayo Clinic. For the last 6 years he has been President of Fondation Ipsen, an international science foundation focused on biotech innovation in Rare Diseases. A physician and scientist, James has published more than 200 articles, six papers in Science and Nature plus articles in journals such as, the New England Journal of Medicine, Lancet and JAMA. He has written four books published in 19 languages in 37 countries. His business training, focused on entrepreneurship, was from Harvard Business School. With a background in wearable technologies, data gathering and data analytics, and with more than 100 patents and trademarks, Levine helped found 35 companies. He was the Innovator of the Year in the state of Minnesota, the World Trade Fair and NASA. Under the Mayo Clinic NEAT Trademarks, Levine’s team delivered scalable health solutions to 72 US corporations. A great deal of James’ work focusses on biotech development, scalable health solutions and business opportunities in underserved regions in the United States, France and low/middle countries such as the Democratic Republic of Congo, Cote d’Ivoire, Afghanistan, Jamaica, Asia, Kenya and India. Consulting to the President of the United States, the US State Department, US Army and internationally, James in 2018 was awarded the President’s Medal for promoting social embeddedness. 300 million people live with rare diseases without effective cures. Sustainable solutions require the efficient use of capital to optimize biotechnology companies, maximize impact and minimize suffering.